Establishes Prescription Drug Affordability Board; appropriates $1 million.
Impact
If enacted, A1747 will significantly affect the state's regulation of the pharmaceutical market. The board's responsibilities include determining affordability challenges posed by drug prices, conducting cost reviews, and developing upper payment limits for certain prescription drugs. This may lead to reduced prices for consumers while also placing regulatory scrutiny on pharmacy benefit managers and manufacturers to ensure that costs are managed transparently. Additionally, the bill encourages collaboration with other states to gather data and promote best practices for drug affordability.
Summary
Assembly Bill A1747 aims to establish a Prescription Drug Affordability Board in New Jersey to address the high costs of prescription drugs affecting residents and state programs. The Board will be responsible for reviewing drug pricing trends, examining the affordability of various pharmaceuticals, and making recommendations for legislative and executive actions to improve drug affordability across New Jersey. Funding for the Board is allocated at $1 million to facilitate its operations, emphasizing the state's commitment to making medications more accessible and financially manageable for its citizens.
Sentiment
The sentiment surrounding A1747 appears to be largely supportive among its sponsors and proponents, mainly due to the urgent need for reform in drug pricing, which has been a critical issue for many healthcare consumers. However, there could be contention from pharmaceutical companies and pharmacy benefits managers who may view the bill as an encroachment on their pricing autonomy. The discussions indicate a recognition of the strain high drug prices place on both the healthcare system and individual patients.
Contention
Notable points of contention include the potential for establishing upper payment limits on drugs, which may meet opposition from pharmaceutical companies who could argue that such regulations could hinder innovation and access to new medications. Additionally, there are concerns about how the board will balance state regulation with federal laws governing drug pricing and distribution. The implications of these regulations may also prompt discussions about how they might affect the availability of certain drugs within the state.
Establishes pilot program in Office of Planning Advocacy to reimburse municipalities for certain expenditures concerning warehouse development; appropriates $1 million.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.